My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Sio Gene Therapies (SIOX)
NASDAQ:SIOX
SIOX nasdaq
United States
Sio Gene Therapies

Sio Gene Therapies Stock Analysis & Ratings

Sio Gene Therapies Stock Analysis Overview

Smart Score
2
Underperform
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Sio Gene Therapies stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

SIOX

SIOX Stock Stats

Previous Close$1.49
Open$1.45
Bid0 x 0
Ask0 x 0
Today’s Range$1.38 - $1.48
52-Week Range$1.38 - $4.15
Volume634.82K
Average Volume1.06M
Market Cap$103.62M
Beta1.56
P/E Ratio-2.3
EPS-0.66
Earnings DateFeb 08, 2022

Company Description

Sio Gene Therapies

Axovant Gene Therapies Ltd. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focus on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis such as Tay-Sachs disease and Sandhoff disease. The company was founded on October 31, 2014 and is headquartered in London, United Kingdom.
Sector
Healthcare
Industry
Biotechnology
CEO
Pavan Cheruvu
Employees
42
ISIN
US8293991043
Address
130 West 42nd Street, New York, NY, 10036, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

SIOX FAQ

What was Sio Gene Therapies’s price range in the past 12 months?
Sio Gene Therapies lowest stock price was $1.38 and its highest was $4.15 in the past 12 months.
    What is Sio Gene Therapies’s market cap?
    Sio Gene Therapies’s market cap is $103.62M.
      What is Sio Gene Therapies’s price target?
      The average price target for Sio Gene Therapies is $7.75. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $10.00 ,the lowest forecast is $6.00. The average price target represents 449.65% Increase from the current price of $1.41.
        What do analysts say about Sio Gene Therapies?
        Sio Gene Therapies’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Sio Gene Therapies’s upcoming earnings report date?
          Sio Gene Therapies’s upcoming earnings report date is Feb 08, 2022 which is in 66 days.
            How were Sio Gene Therapies’s earnings last quarter?
            Sio Gene Therapies released its earnings results on Nov 12, 2021. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.17 by -$0.12.
              Is Sio Gene Therapies overvalued?
              According to Wall Street analysts Sio Gene Therapies’s price is currently Undervalued.
                Does Sio Gene Therapies pay dividends?
                Sio Gene Therapies does not currently pay dividends.
                What is Sio Gene Therapies’s EPS estimate?
                Sio Gene Therapies’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Sio Gene Therapies have?
                Sio Gene Therapies has 73,490,000 shares outstanding.
                  What happened to Sio Gene Therapies’s price movement after its last earnings report?
                  Sio Gene Therapies reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.17. Following the earnings report the stock price went down -6.965%.
                    Which hedge fund is a major shareholder of Sio Gene Therapies?
                    Among the largest hedge funds holding Sio Gene Therapies’s share is PRIMECAP Management Co. It holds Sio Gene Therapies’s shares valued at 112K.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis